Ocumension Therapeutics

5DG

Company Profile

  • Business description

    Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

  • Contact

    No. 1858 Yinzhongnan Road
    Guoxiang Subdistrict
    Wuzhong District
    SuzhouJiangsu
    CHN

    T: +86 2161493800

    https://www.ocumension.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    489

Stocks News & Analysis

stocks

Our view of BHP after June quarter results

Record copper volumes are reported.
stocks

James Hardie transfers of share listing to New York Stock Exchange

The change is a result of the controversial Azek acquisition.
stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.2080.60-0.89%
CAC 407,798.2224.45-0.31%
DAX 4024,307.8018.290.08%
Dow JONES (US)44,484.13141.940.32%
FTSE 1009,012.9920.870.23%
HKSE24,994.14168.480.68%
NASDAQ21,026.24130.590.62%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,961.5181.110.63%
S&P 5006,325.1628.370.45%
S&P/ASX 2008,668.2089.00-1.02%
SSE Composite Index3,559.7925.310.72%

Market Movers